Which medications in the drug class Vascular Endothelial Growth Factor (VEGF) Inhibitors are used in the treatment of Central Retinal Vein Occlusion (CRVO)?

Updated: Apr 18, 2019
  • Author: Lakshmana M Kooragayala, MD; Chief Editor: Douglas R Lazzaro, MD, FAAO, FACS  more...
  • Print

Vascular Endothelial Growth Factor (VEGF) Inhibitors

These agents bind to VEGF-A receptors to arrest macular edema and improve visual acuity associated with CVRO.

Ranibizumab (Lucentis)

VEGF antibody. Indicated for macular edema following retinal vein occlusion.

Aflibercept intravitreal (Eylea)

Binds and prevents activation of vascular endothelial growth factors (VEGF-A) and placental growth factor (PIGF). Activation of VEGF-A and PIGF can result in neovascularization and vascular permeability. It is indicated for treatment of macular edema following retinal vein occlusion (branched or central retinal vein occlusion).

Bevacizumab (Avastin)

Bevacizumab (Avastin, Genentech, Inc.) is a recombinant, humanized monoclonal antibody that binds all isoforms of VEGF-A. It is used as an off-label medication in various ocular conditions associated with up-regulation of VEGF and increased vascular permeability and neovascularization.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!